ARTICLE | Company News
Vernalis, AstraZeneca deal
October 20, 2003 7:00 AM UTC
AZN will use VER's structure-based drug discovery (SBDD) technology to study AZN compounds against anti-infective targets. SBDD was developed by RiboTargets Ltd., which was acquired by British Biotec...